Mark Friedman

Dr. Friedman joined Axogen in September of 2006. During his tenure with Axogen, he has held positions of increasing responsibility across Quality Assurance and Regulatory Affairs. With over 35 years of industry experience, he has worked for large, medium, and startup healthcare companies, developing quality systems and regulatory strategies for both domestic and international. He has a diverse background, including academic research on human protein and monoclonal antibodies and, in industry, for developing human tissue, medical device, and biological product technologies. He has negotiated complex agreements with the US FDA and with international regulatory agencies. Dr. Friedman has a Ph.D. in Chemistry specializing in protein biochemistry from the University of Cincinnati with undergraduate work from Centre College of Kentucky.